Culture-negative vertebral osteomyelitis after antibiotics: specimen handling and a single positive bottle
A 46-year-old man with poorly controlled type 2 diabetes has three months of progressive low back pain, fever of 38.3 °C, CRP 96 mg/L and a white cell count of 11.2 × 10^9/L. MRI shows L4–L5 discitis with an epidural component and a small paravertebral collection. Two sets of blood cultures taken before admission are negative at five days. He had received ten days of oral ciprofloxacin from a private clinic. CT-guided biopsy of the disc space yields 2 mL of purulent fluid in a syringe, transported dry at room temperature and received in the laboratory six hours later. Gram stain shows no organisms; bacterial culture on blood agar and MacConkey agar is negative at 48 hours. The treating team wants to stop antibiotics and repeat the biopsy; the infectious disease consultant requests 16S rRNA PCR. The laboratory has no on-site molecular facility and sends samples to a reference centre three days a week.
1. Why are the cultures negative, and how should the biopsy have been handled?
Read the worked answer
The most important reason is the ten days of oral ciprofloxacin, which suppresses but does not necessarily eradicate the organism; vertebral osteomyelitis has a low organism burden even before antibiotics. Other reasons include fastidious organisms (Brucella, Kingella, mycobacteria, fungi, anaerobes), a 2 mL sample in a dry syringe with a six-hour delay, and routine media that do not support mycobacteria or fungi. The negative result at 48 hours says nothing about those organisms.
Correct handling: obtain the biopsy before antibiotics whenever possible; send tissue in anaerobic transport medium and sterile saline for culture and histology; inoculate aerobic and anaerobic blood culture bottles at the bedside; perform Gram stain, mycobacterial culture (LJ or MGIT), fungal culture and Brucella culture; hold bacterial cultures for 14 days; send material for 16S rRNA PCR and sequencing. Avoid swabs, which dry out and yield poor material. If the patient is already on antibiotics, note this on the request form so that the laboratory interprets the culture appropriately and holds it longer.
2. After re-biopsy, Staphylococcus aureus grows in one of two blood culture bottles at 36 hours. Is this a contaminant? How does it change management?
Read the worked answer
No - Staphylococcus aureus is never dismissed as a contaminant from a deep bone or disc biopsy, even when it grows in only one bottle. Coagulase-negative staphylococci in a single bottle would be treated as probable contamination, but S. aureus is a recognized cause of vertebral osteomyelitis and bacteraemia. Confirm the Gram stain and subculture, identify to species level, and determine methicillin susceptibility.
Management: notify the treating team as a critical result. For MSSA, high-dose IV flucloxacillin or cefazolin (or an oral regimen with high bioavailability once the patient is stable); for MRSA, vancomycin with AUC-guided dosing or daptomycin. The duration for vertebral osteomyelitis with an epidural component is typically six weeks of pathogen-directed therapy after source control, with repeat blood cultures until negative and serial CRP monitoring. The result also justifies stopping empirical broad-spectrum cover. If 16S PCR had been positive with a negative culture, it would have supported pathogen-directed therapy; a negative PCR does not exclude infection because of inhibitors and low organism load.
3. How would you integrate the PCR result and plan duration, given the reference laboratory's three-day-per-week schedule?
Read the worked answer
Send tissue for 16S rRNA PCR in parallel with culture, not instead of it. The result may take three to seven days given batching and courier transport, so empirical therapy should not be delayed. If PCR identifies S. aureus while culture is negative, treat as staphylococcal osteomyelitis on the basis of sequencing plus the MRI and clinical picture; if PCR is negative, it does not exclude infection and culture results still govern. State the expected turnaround time on the report and agree a courier schedule with the reference laboratory, ideally with a daily or alternate-day dispatch rather than a three-day batch.
Duration: six weeks of targeted therapy from the re-biopsy or from source control, with neurosurgical assessment of the epidural component and ID follow-up. Do not stop antibiotics simply because earlier cultures were negative; if the patient is improving on empirical treatment, continue and reassess. The laboratory's role is to communicate uncertainty honestly, flag the prior antibiotic exposure in the report, and ensure the PCR result is acted on rather than filed after discharge. Audit turnaround times for referred molecular tests as a quality indicator.